News stories about STRATA Skin Sciences (NASDAQ:SSKN) have trended somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. STRATA Skin Sciences earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 45.5141756346912 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of research firms have recently weighed in on SSKN. Zacks Investment Research raised shares of STRATA Skin Sciences from a “hold” rating to a “strong-buy” rating and set a $2.00 price objective for the company in a research report on Tuesday, June 5th. HC Wainwright set a $3.00 price objective on shares of STRATA Skin Sciences and gave the company a “buy” rating in a research report on Thursday, May 31st. Finally, ValuEngine raised shares of STRATA Skin Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st.
STRATA Skin Sciences traded up $0.15, hitting $2.24, on Tuesday, Marketbeat.com reports. 389,224 shares of the company were exchanged, compared to its average volume of 171,300. STRATA Skin Sciences has a twelve month low of $1.06 and a twelve month high of $2.81. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.81 and a current ratio of 1.15. The firm has a market capitalization of $14.12 million, a price-to-earnings ratio of 1.14 and a beta of 0.75.
STRATA Skin Sciences (NASDAQ:SSKN) last issued its quarterly earnings results on Monday, April 2nd. The medical device company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($1.27) by $1.17. STRATA Skin Sciences had a negative net margin of 60.23% and a negative return on equity of 36.19%. The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $7.35 million. equities analysts forecast that STRATA Skin Sciences will post -0.23 EPS for the current fiscal year.
In related news, Director Samuel E. Navarro purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 5th. The stock was purchased at an average price of $2.01 per share, with a total value of $40,200.00. Following the completion of the transaction, the director now owns 7,000 shares of the company’s stock, valued at approximately $14,070. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Luann Via purchased 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The shares were bought at an average cost of $2.14 per share, with a total value of $53,500.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $10,700. The disclosure for this purchase can be found here. Insiders have purchased 63,000 shares of company stock valued at $128,090 in the last ninety days. 9.95% of the stock is currently owned by company insiders.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma.
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.